Searched for
ELI LILLY TRILLION VALUATION
NSE IPO to value exchange at Rs 5 lakh crore? 2 scenarios every investor should watchNSE's proposed IPO could value the exchange at around Rs 5 lakh crore, making it one of India's most valuable listed financial institutions...- US stocks | Micron overtakes Meta, Tesla in market value amid relentless AI infrastructure demandMemory chip giant Micron Technology has surpassed Meta Platforms in market valuation for the first time, driven by a robust AI-fueled surge...
- OpenAI leans toward waiting until next year for IPO, NYT reportsOpenAI may postpone its highly anticipated public launch until 2027, setting its sights on an ambitious $1 trillion valuation that CEO Sam ...
- Centre set to tighten oversight of pharma packaging materialsIndia is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This mov...
- Eli Lilly launches cancer drug Tanstrive in IndiaThe launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced ...
- SK Hynix surges 12% as US listing plan boosts valuation hopesSK Hynix shares surged as much as 12% after the memory chipmaker unveiled plans for a $29 billion US listing, boosting hopes of higher valu...
- Elon Musk loses trillionaire status as SpaceX rally fadesElon Musk's net worth has dipped below the trillion-dollar mark following a significant slump in SpaceX and Tesla shares. Just weeks after ...
- Elon Musk net worth declines below $1 trillion: World’s first trillionaire loses elite status as SpaceX stocks slide and Tesla slump hit fortuneElon Musk net worth: Elon Musk's reign as the world's first trillionaire has been short-lived. A significant drop in SpaceX shares followin...
- SpaceX shares extend slide with another 3% fall; over $600 billion in market value wiped out in 3 sessionsSpaceX shares fell another 3%, extending a three-day selloff that has wiped out over $600 billion in market value and pushed the stock belo...
- Jio Platforms' debut could give RIL top 2 slots in Indian m-cap leagueMukesh Ambani's Reliance group is set to significantly boost its market presence, potentially holding nearly 7% of BSE's total market capit...
- SpaceX valuation hinges on uncertain AI economics, says Professor Aswath DamodaranSpaceX's massive market debut, reaching a $2 trillion valuation, is largely fuelled by AI ambitions, according to valuation expert Aswath D...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- India's Electronics Mart eyes new markets as tech hubs fear job lossesElectronics Mart India is diversifying its store presence beyond Hyderabad due to concerns about potential AI-driven job losses impacting c...
- Eli Lilly's Alzheimer's drug donanemab approved in India, but neurologists flag cost, access barriersA new drug for Alzheimer's, donanemab, has arrived in India. It aims to slow the disease's progression by clearing brain plaques. While off...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- UK approves Novo weight-loss pill to edge open European marketBritain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...
- US stocks: Musk's SpaceX prices record $75 billion IPO at $135 a shareSpaceX has priced its record-breaking U.S. IPO at $135 per share, raising $75 billion and valuing the company at $1.77 trillion. This makes...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefitsEli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...
Load More
